Glucagon Function Drives Multi-Billion Dollar Peptide Therapeutics Market Trends
Abstract: Glucagon’s role in glucose homeostasis drives a multi-billion dollar peptide therapeutics market, with GLP-1 receptor agonists (e.g., semaglutide) dominating 2024 sales. Key trends include a shift toward dual/triple agonists (e.g., tirzepatide) for enhanced efficacy. Brand comparison reveals Novo Nordisk’s patent-protected Ozempic vs. generic alternatives with lower purity (≥95% vs. ≥98%). Technical advantages (high specificity, low toxicity) are offset by poor oral bioavailability (<1%) requiring injection. Product parameters (purity, endotoxin levels) and factory GMP certifications (FDA, EU) are critical for quality. Market growth (CAGR 15.2%) is fueled by obesity/diabetes applications, with logistics requiring cold-chain (2–8°C) stability. Selection criteria prioritize certified suppliers and third-party HPLC/LC-MS validation.